The stock of Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) last traded at $36.10, up 0.50% from the previous session.
Data from the available sources indicates that Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is covered by 6 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $51.00 and a low of $41.00, we find $50.00. Given the previous closing price of $35.92, this indicates a potential upside of 39.2 percent. AMLX stock price is now -0.30% away from the 50-day moving average and 23.95% away from the 200-day moving average. The market capitalization of the company currently stands at $2.35B.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
In total, 1 analysts have assigned it a hold rating, and 5 have given it a buy rating. Brokers who have rated the stock have averaged $48.40 as their price target over the next twelve months.
With the price target of $50, BofA Securities recently initiated with Buy rating for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX). On May 25, 2022, Citigroup recently initiated its ‘Buy’ rating on the stock quoting a target price of $21, while ‘Goldman’ rates the stock as ‘Neutral’.
In other news, Morningside Venture Investment, 10% Owner sold 50,000 shares of the company’s stock on Mar 02. The stock was sold for $1,687,500 at an average price of $33.75. Upon completion of the transaction, the 10% Owner now directly owns 7,480,598 shares in the company, valued at $270.05 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 24, Chief Legal Officer Mazzariello Gina sold 3,586 shares of the business’s stock. A total of $123,672 was realized by selling the stock at an average price of $34.49. This leaves the insider owning 37,414 shares of the company worth $1.35 million. Insiders disposed of 1,437,275 shares of company stock worth roughly $51.89 million over the past 1 year. A total of 24.57% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AMLX stock. A new stake in Amylyx Pharmaceuticals Inc. shares was purchased by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) during the first quarter worth $97,217,000. PICTET ASSET MANAGEMENT SA invested $40,496,000 in shares of AMLX during the first quarter. In the first quarter, EVENTIDE ASSET MANAGEMENT, LLC acquired a new stake in Amylyx Pharmaceuticals Inc. valued at approximately $9,025,000. IRON TRIANGLE PARTNERS LP acquired a new stake in AMLX for approximately $8,673,000. GREAT POINT PARTNERS I LP purchased a new stake in AMLX valued at around $6,859,000 in the second quarter. In total, there are 157 active investors with 65.70% ownership of the company’s stock.
With an opening price of $36.12 on Wednesday morning, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) set off the trading day. During the past 12 months, Amylyx Pharmaceuticals Inc. has had a low of $6.51 and a high of $41.93. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.30, and a quick ratio of 5.30. The fifty day moving average price for AMLX is $36.21 and a two-hundred day moving average price translates $29.12 for the stock.
The latest earnings results from Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.92, beating analysts’ expectations of -$0.97 by 0.05. This compares to -$3.42 EPS in the same period last year. The company reported revenue of $0.34 million for the quarter, compared to $0.28 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 21.05 percent. For the current quarter, analysts expect AMLX to generate $3.1M in revenue.
Amylyx Pharmaceuticals Inc.(AMLX) Company Profile
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company’s product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
